A first-in-class, narrow-spectrum, oral antibiotic for the treatment of Clostridium difficile-associated diarrhea, and prevention of recurrences.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Laquinimod
An oral immunomodulator for the treatment of relapsing remitting multiple sclerosis.
Ion™ Stent for Acute Myocardial Infarction
A paclitaxel-eluting, platinum chromium alloy stent intended for use in patients undergoing primary angioplasty to treat acute ST-segment elevation myocardial infarction.
Raven Mobile Surgical Robot
A mobile, lightweight, modular robotic surgical system designed to perform telesurgery over long distances.
Zelboraf® (Vemurafenib, PLX 4032)
An oral BRAF inhibitor for the treatment of late-stage metastatic melanoma with the gene mutation BRAF V600E.
Kalydeco™ (VX-770, Ivacaftor)
An oral cystic fibrosis transmembrane regulator potentiator for the treatment of cystic fibrosis in patients aged 6 years or older who have the rare G551D variant in the CFTR gene.
NanoKnife® System
A minimally invasive system that uses irreversible electroporation for surgical ablation of soft tissue.
LY3009104 (INCB028050)
An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Microsurgical Autologous Lymph Node Transfer (ALNT) for Postmastectomy Lymphedema
A microsurgical technique for the treatment of chronic refractory postmastectomy lymphedema, performed with or without concomitant breast reconstruction.
Erivedge™ (Vismodegib)
Targeted oral therapy for the treatment of adults with advanced basal cell carcinoma who are not appropriate surgical candidates.